BRAINSTORM CELL THERAPEUTICS's ticker is BCLI and the CUSIP is 10501E201. A total of 82 filers reported holding BRAINSTORM CELL THERAPEUTICS in Q2 2020. The put-call ratio across all filers is 0.48 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $424,000 | -2.5% | 114,318 | +21.7% | 0.01% | -20.0% |
| Q4 2020 | $435,000 | -52.6% | 93,902 | +65.9% | 0.01% | -65.5% |
| Q3 2020 | $917,000 | +58.4% | 56,617 | +8.4% | 0.03% | +38.1% |
| Q2 2020 | $579,000 | +93.6% | 52,216 | -21.1% | 0.02% | +50.0% |
| Q1 2020 | $299,000 | +15.4% | 66,197 | +9.8% | 0.01% | +55.6% |
| Q4 2019 | $259,000 | -2.6% | 60,313 | -12.1% | 0.01% | -10.0% |
| Q3 2019 | $266,000 | +57.4% | 68,647 | +61.7% | 0.01% | +100.0% |
| Q2 2019 | $169,000 | -39.9% | 42,450 | -34.4% | 0.01% | -64.3% |
| Q1 2019 | $281,000 | +18.6% | 64,710 | -3.1% | 0.01% | +27.3% |
| Q4 2018 | $237,000 | +63.4% | 66,797 | +75.8% | 0.01% | +120.0% |
| Q3 2018 | $145,000 | +42.2% | 37,988 | +30.8% | 0.01% | -28.6% |
| Q2 2018 | $102,000 | +6.2% | 29,052 | -3.3% | 0.01% | +16.7% |
| Q1 2018 | $96,000 | +5.5% | 30,053 | +20.0% | 0.01% | -14.3% |
| Q4 2017 | $91,000 | +15.2% | 25,045 | +29.9% | 0.01% | 0.0% |
| Q3 2017 | $79,000 | +5.3% | 19,285 | +6.5% | 0.01% | +16.7% |
| Q2 2017 | $75,000 | – | 18,107 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ABNER HERRMAN & BROCK LLC | 239,000 | $2,679,000 | 0.48% |
| EAM Investors, LLC | 81,854 | $918,000 | 0.20% |
| CFO4Life Group, LLC | 12,003 | $135,000 | 0.05% |
| Phoenix Holdings Ltd. | 104,782 | $1,112,000 | 0.05% |
| WINTON GROUP Ltd | 118,487 | $1,328,000 | 0.03% |
| Merit Financial Group, LLC | 28,731 | $322,000 | 0.03% |
| HighPoint Advisor Group LLC | 13,533 | $151,000 | 0.03% |
| SHANDA ASSET MANAGEMENT HOLDINGS Ltd | 23,000 | $258,000 | 0.02% |
| ETF MANAGERS GROUP, LLC | 52,216 | $579,000 | 0.02% |
| IHT Wealth Management, LLC | 13,000 | $146,000 | 0.02% |